- Home
- SLRX vs QLGN Comparison
SLRX vs QLGN Comparison
Compare SLRX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- QLGN
- Stock Information
- Founded
- SLRX N/A
- QLGN 1996
- Country
- SLRX United States
- QLGN United States
- Employees
- SLRX N/A
- QLGN N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- QLGN Health Care
- Exchange
- SLRX Nasdaq
- QLGN Nasdaq
- Market Cap
- SLRX 2.5M
- QLGN 2.7M
- IPO Year
- SLRX N/A
- QLGN N/A
- Fundamental
- Price
- SLRX $1.37
- QLGN $4.83
- Analyst Decision
- SLRX
- QLGN
- Analyst Count
- SLRX 0
- QLGN 0
- Target Price
- SLRX N/A
- QLGN N/A
- AVG Volume (30 Days)
- SLRX 42.5K
- QLGN 144.8K
- Earning Date
- SLRX 11-14-2024
- QLGN 11-14-2024
- Dividend Yield
- SLRX N/A
- QLGN N/A
- EPS Growth
- SLRX N/A
- QLGN N/A
- EPS
- SLRX N/A
- QLGN N/A
- Revenue
- SLRX N/A
- QLGN N/A
- Revenue This Year
- SLRX N/A
- QLGN N/A
- Revenue Next Year
- SLRX N/A
- QLGN N/A
- P/E Ratio
- SLRX N/A
- QLGN N/A
- Revenue Growth
- SLRX N/A
- QLGN N/A
- 52 Week Low
- SLRX $1.26
- QLGN $3.34
- 52 Week High
- SLRX $7.27
- QLGN $39.15
- Technical
- Relative Strength Index (RSI)
- SLRX 41.48
- QLGN 45.01
- Support Level
- SLRX $1.37
- QLGN $3.34
- Resistance Level
- SLRX $1.44
- QLGN $4.56
- Average True Range (ATR)
- SLRX 0.07
- QLGN 0.58
- MACD
- SLRX -0.01
- QLGN 0.15
- Stochastic Oscillator
- SLRX 15.61
- QLGN 82.69
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.